Doublecortin Antibody (OTI4A3) [PerCP]
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-70558PCP
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Validated:
Human, Mouse, Rat
Applications
Flow Cytometry, Immunocytochemistry/ Immunofluorescence
Label
PerCP (Excitation = 490 nm, Emission = 675 nm)
Antibody Source
Monoclonal Mouse IgG1 Clone # OTI4A3
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Summary for Doublecortin Antibody (OTI4A3) [PerCP]
Immunogen
Full length recombinant protein of human Doublecortin (NP_835365) produced in HEK293T cells.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1
Applications for Doublecortin Antibody (OTI4A3) [PerCP]
Application
Recommended Usage
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Immunocytochemistry/ Immunofluorescence
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Immunogen affinity purified
Formulation
PBS
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: Doublecortin/DCX
Long Name
Doublecortin
Alternate Names
DBCN, Doublecortex, Doublin, Lis-X, LISX
Gene Symbol
DCX
Additional Doublecortin/DCX Products
Product Documents for Doublecortin Antibody (OTI4A3) [PerCP]
Product Specific Notices for Doublecortin Antibody (OTI4A3) [PerCP]
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...